Idiopathic Venous Thromboembolism

  • Crina SinescuEmail author


Venous thromboembolism is a manifest disease that includes deep vein thrombosis and pulmonary embolism. It is the third most common cardiovascular disorder after coronary artery disease and stroke.


Right Ventricular Deep Vein Thrombosis Dabigatran Etexilate Right Ventricular Dysfunction Proximal Deep Vein Thrombosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Antiphospholipid antibody syndrome


Compression ultrasonography


Deep vein thrombosis


High density lipoprotein




Low density lipoprotein


Low molecular weight heparin


Multi-detector computer tomography


Pulmonary embolism


Right ventricle


Residual vein thrombosis


Single-detector computer tomography


Vitamin K antagonists


Venous thromboembolism


Venous thrombotic event


  1. 1.
    Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16.PubMedGoogle Scholar
  3. 3.
    Torbicki A, Perrier A, Konstantinides S, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–315.Google Scholar
  4. 4.
    Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am J Med. 2005;118:978–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277:642–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435–41.PubMedCrossRefGoogle Scholar
  7. 7.
    Spencer FA, Ginsberg JS, Chong A, Alter DA. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J Thromb Haemost. 2008;6:1507–13.PubMedGoogle Scholar
  8. 8.
    Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet. 2007;370:1773–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008;117:93–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Jang MJ, Choi WI, Bang SM, Lee T, Kim YK, Ageno W, et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol. 2009;29:311–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Steffen LM, Cushman M, Peacock JM, Heckbert SR, Jacobs Jr DR, Rosamond WD, et al. Metabolic syndrome and risk of venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology. J Thromb Haemost. 2009;7:746–51.PubMedCrossRefGoogle Scholar
  12. 12.
    Steffen LM, Folsom AR, Cushman M, Jacobs Jr DR, Rosamond WD. Greater fish, fruit, and vegetable intakes are related to lower incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Circulation. 2007;115:188–95.PubMedCrossRefGoogle Scholar
  13. 13.
    Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–33.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosengren A, Freden M, Hansson PO, Wilhelmsen L, Wedel H, Eriksson H. Psychosocial factors and venous thromboembolism: a long-term follow-up study of Swedish men. J Thromb Haemost. 2008;6:558–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism: a prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102:615–9.PubMedGoogle Scholar
  17. 17.
    Luxembourg B, Schmitt J, Humpich M, Glowatzki M, Dressler D, Seifried E, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost. 2009;102:668–75.PubMedGoogle Scholar
  18. 18.
    Zee RY, Glynn RJ, Cheng S, Steiner L, Rose L, Ridker PM. An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2:57–62.PubMedCrossRefGoogle Scholar
  19. 19.
    Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851–61.PubMedCrossRefGoogle Scholar
  20. 20.
    van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med. 2008;168:21–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation. 2004;110:1605–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–35.PubMedCrossRefGoogle Scholar
  24. 24.
    Bounameaux H, Perrier A, Righini M. Diagnosis of venous thromboembolism: an update. Vasc Med. 2010;15(5):399–406.PubMedCrossRefGoogle Scholar
  25. 25.
    Klok FA, Kruisman E, Spaan J, et al. Comparison of the revised Geneva score with the Wells rule for assessing clinical probability of pulmonary embolism. J Thromb Haemost. 2008;6(1):40–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Klok FA, Mos IC, Nijkeuter M, et al. Simplification of the revised Geneva score for assessing clinical probability of pulmonary embolism. Arch Intern Med. 2008;168(19):2131–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Kahn SR. The post thrombotic syndrome. Thromb Res. 2011;127 Suppl 3:S89–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al. Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J. 1997;18(7):1141–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. 1992;19(2):239–45.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group. Chest. 1994;106(3):718–24.PubMedCrossRefGoogle Scholar
  31. 31.
    Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24(1):28–66.PubMedCrossRefGoogle Scholar
  32. 32.
    Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22. doi: 10.2165/0003088-200948010-00001.PubMedCrossRefGoogle Scholar
  33. 33.
    Perzborn E, Roehrig S, Straub A, Kubitza D, Mueck W, Laux V. Rivaroxaban: a new oral factor xa inhibitor. Arterioscler Thromb Vasc Biol. 2010;30(3):376–81.PubMedCrossRefGoogle Scholar
  34. 34.
    Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)—an oral, direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120(5):685–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4(1):121–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22): 2374–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3(11):2479–86.PubMedCrossRefGoogle Scholar
  38. 38.
    Kwong LM. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty. Am J Manag Care. 2011;17(1):S22–6.PubMedGoogle Scholar
  39. 39.
    Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT doseranging study. J Thromb Haemost. 2008;6(8):1313–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet. 2010;375(9717):807–15.PubMedCrossRefGoogle Scholar
  41. 41.
    Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–98.PubMedCrossRefGoogle Scholar
  42. 42.
    Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–56.PubMedCrossRefGoogle Scholar
  43. 43.
    Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–85.PubMedCrossRefGoogle Scholar
  44. 44.
    Goldhaber SZ, Piazza G. Optimal duration of anticoagulation after venous thromboembolism. Circulation. 2011;123(6):664–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010;138(5):1093–100.PubMedCrossRefGoogle Scholar
  46. 46.
    Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. Epub 2010 Aug 29.PubMedCrossRefGoogle Scholar
  47. 47.
    Heit JA, Mohr DN, Silverstein MD, Petterson TM, O’Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients. Haematologica. 2007;92:199–205.PubMedCrossRefGoogle Scholar
  50. 50.
    Vossen CY, Walker ID, Svensson PJ, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol. 2005;25:1992–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.PubMedCrossRefGoogle Scholar
  52. 52.
    Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301:2472–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166:729–36.PubMedCrossRefGoogle Scholar
  54. 54.
    Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Kyrle PA, Minar E, Hirschl M, et al. High plasma factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–62.PubMedCrossRefGoogle Scholar
  56. 56.
    den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood. 2007;109:139–44.CrossRefGoogle Scholar
  57. 57.
    Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med. 2007;146:761–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Nijkeuter M, Sohne M, Tick LW, Kamphuisen PW, Kramer MH, Laterveer L, et al. The natural course of hemodynamically stable pulmonary embolism: clinical outcome and risk factors in a large prospective cohort study. Chest. 2007;131:517–23.PubMedCrossRefGoogle Scholar
  59. 59.
    Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558–63.PubMedCrossRefGoogle Scholar
  60. 60.
    Eichinger S, Hron G, Bialonczyk C, Hirschl M, Minar E, Wagner O, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168:1678–83.PubMedCrossRefGoogle Scholar
  61. 61.
    Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, Kyrle PA, et al. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation. 2007;115:1609–14.PubMedCrossRefGoogle Scholar
  62. 62.
    Eichinger S, Weltermann A, Minar E, Stain M, Schonauer V, Schneider B, et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med. 2004;164:92–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna Prediction Model. Circulation. 2010;121:1630–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149:481–90.PubMedCrossRefGoogle Scholar
  65. 65.
    Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Cosmi B, Legnani C, Tosetto A, et al. Sex, age, and normal post-anticoagulation D-dimer as risk factors or recurrence after idiopathic venous thromboembolism in the PROLONG study extension. J Thromb Haemost. 2010;8(9):1933–42.PubMedCrossRefGoogle Scholar
  67. 67.
    Siragusa S, Malato A, Anastasio R, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2010;112:511–5.CrossRefGoogle Scholar
  68. 68.
    Prandoni P, Prins MH, Lensing AW, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med. 2009;150:577–85.PubMedCrossRefGoogle Scholar
  69. 69.
    Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. Can Med Assoc J. 2008;179:417–26.CrossRefGoogle Scholar
  70. 70.
    Cosmi B, Legnani C, Iorio A, et al. Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the Prolong Study. Eur J Vasc Endovasc Surg. 2010;39:356–65.PubMedCrossRefGoogle Scholar
  71. 71.
    Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsey T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Rosovsky R, Lee AY. Evidence-based mini-review: should all patients with idiopathic venous thromboembolic events be screened extensively for occult malignancy? Hematology Am Soc Hematol Educ Program. 2010;2010:150–2.PubMedCrossRefGoogle Scholar
  75. 75.
    Bauer KA. Duration of anticoagulation: applying the guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2010;2010:210–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  1. 1.Department of CardiologyCarol Davila University of MedicineBucharestRomania

Personalised recommendations